Compare Johnson & Johnson (JNJ) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nokia Corp — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Johnson & Johnson is far larger — about 10.8× Nokia Corp's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Nokia Corp for 66 Days on average.
| JNJ | NOK | |
|---|---|---|
Market Cap | $618.09B | $56.99B |
Volume | 6,050,983 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $278.43 | $16.83 |
52-Week Low | $186.00 | $5.25 |
Typical Hold Time | 129 Days | 66 Days |
Enterprise Value | $646.37B | $55.01B |
Dividend Yield | 2.09% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Nokia (NOK) trades at $10.14, down 4.52% today, amid bearish technical signals but strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 75.09 but improving revenue trends, with 2026 revenue projected at $20.4B. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Cash flow volatility remains a concern with negative net cash flow in 2025 and 2026.
The outlook is cautiously optimistic with a consensus price target of $17.50 representing 73% upside potential. Key opportunities include AI infrastructure demand and expanding partnerships, while risks involve cash flow instability and competitive pressures in telecom equipment. Analyst sentiment is strongly bullish with 62% buy ratings, though technical indicators suggest near-term weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
